Amyloid precursor protein-mediated free radicals and oxidative damage: Implications for the development and progression of Alzheimer's disease

被引:301
作者
Reddy, PH [1 ]
机构
[1] Oregon Hlth & Sci Univ, Inst Neurol Sci, Neurogenet Lab, Beaverton, OR 97006 USA
关键词
in vitro studies; mitochondria; mitochondrial gene expression; oxidative damage; reactive oxygen species; transgenic mice;
D O I
10.1111/j.1471-4159.2005.03530.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Alzheimer's disease (AD) is a late-onset dementia that is characterized by the loss of memory and an impairment of multiple cognitive functions. Advancements in molecular, cellular, and animal model studies have revealed that the formation of amyloid beta (A beta) and other derivatives of the amyloid precursor protein (APP) are key factors in cellular changes in the AD brain, including the generation of free radicals, oxidative damage, and inflammation. Recent molecular, cellular, and gene expression studies have revealed that A beta enters mitochondria, induces the generation of free radicals, and leads to oxidative damage in post-mortem brain neurons from AD patients and in brain neurons from cell models and transgenic mouse models of AD. In the last three decades, tremendous progress has been made in mitochondrial research and has provided significant findings to link mitochondrial oxidative damage and neurodegenerative diseases such as AD. Researchers in the AD field are beginning to recognize the possible involvement of a mutant APP and its derivatives in causing mitochondrial oxidative damage in AD. This article summarizes the latest research findings on the generation of free radicals in mitochondria and provides a possible model that links A beta proteins, the generation of free radicals, and oxidative damage in AD development and progression.
引用
收藏
页码:1 / 13
页数:13
相关论文
共 115 条
  • [1] Ahlemeyer B, 2003, PHARMACOPSYCHIATRY, V36, pS8
  • [2] Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease:: a double blind, randomized and placebo-controlled trial
    Akhondzadeh, S
    Noroozian, M
    Mohammadi, M
    Ohadinia, S
    Jamshidi, AH
    Khani, M
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2003, 28 (01) : 53 - 59
  • [3] Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease:: a double blind, randomised, placebo controlled trial
    Akhondzadeh, S
    Noroozian, M
    Mohammadi, M
    Ohadinia, S
    Jamshidi, AH
    Khani, M
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2003, 74 (07) : 863 - 866
  • [4] Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells
    Anandatheerthavarada, HK
    Biswas, G
    Robin, MA
    Avadhani, NG
    [J]. JOURNAL OF CELL BIOLOGY, 2003, 161 (01) : 41 - 54
  • [5] The NADPH oxidase of endothelial cells
    Babior, BM
    [J]. IUBMB LIFE, 2000, 50 (4-5) : 267 - 269
  • [6] The neutrophil NADPH oxidase
    Babior, BM
    Lambeth, JD
    Nauseef, W
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2002, 397 (02) : 342 - 344
  • [7] Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424
  • [8] Behl C, 2005, SUB CELL BIOCHEM, V38, P65
  • [9] HYDROGEN-PEROXIDE MEDIATES AMYLOID-BETA PROTEIN TOXICITY
    BEHL, C
    DAVIS, JB
    LESLEY, R
    SCHUBERT, D
    [J]. CELL, 1994, 77 (06) : 817 - 827
  • [10] Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease
    Bosetti, F
    Brizzi, F
    Barogi, S
    Mancuso, M
    Siciliano, G
    Tendi, EA
    Murri, L
    Rapoport, SI
    Solaini, G
    [J]. NEUROBIOLOGY OF AGING, 2002, 23 (03) : 371 - 376